Adipose tissue plays essential roles in maintaining lipid and glucose homeostasis. To date
several types of adipose tissue have been identified, namely white, brown, and beige, that …

Abstract Type 2 diabetes (T2D) is a widely prevalent disease with substantial economic and
social impact for which multiple conventional and novel pharmacotherapies are currently …

Potentiation of glucagon-like peptide-1 (GLP-1) action through selective GLP-1 receptor
(GLP-1R) agonism or by prevention of enzymatic degradation by inhibition of dipeptidyl …

Background: Clinicians and patients need updated evidence on the comparative
effectiveness and safety of diabetes medications to make informed treatment choices …

Background Despite a broad range of pharmacological options for the treatment of type 2
diabetes, optimum glycaemic control remains challenging for many patients and new …

Aim The aim of this trial was to investigate the mechanism of action for body weight loss with
semaglutide. Materials and methods This randomised, double‐blind, placebo‐controlled …

The effectiveness of a drug is dependent on accumulation at the site of action at therapeutic
levels, however, challenges such as rapid renal clearance, degradation or non-specific …

Background Semaglutide is a novel glucagon-like peptide-1 (GLP-1) analogue, suitable for
once-weekly subcutaneous administration, in development for treatment of type 2 diabetes …

Obesity is a chronic disease with high prevalence and associated comorbidities, making it a
growing global concern. These comorbidities include type 2 diabetes, hypertension …

Aims To compare efficacy and safety of glucagon‐like peptide‐1 receptor agonists (GLP‐
1RAs) in people with type 2 diabetes. Materials and methods We electronically searched, up …